Technological Aspects of Ensuring the Specific Safety of Human Immunoglobulin and Albumin Preparations


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Modern technological approaches to ensuring the specific safety of human immunoglobulin and albumin preparations are analyzed. Introduction into human immunoglobulin preparation technology of donor screening for group- and rhesus-affiliations and chromatographic purification steps to reduce the contents of anti-A and anti-B hemagglutinins and anti-D antibodies are shown to be promising. Technological capabilities for reducing the anticomplementary activity and thrombogenic potential of immunoglobulin preparations and decreasing the contents of prekallikrein activator in human i.v. immunoglobulin and albumin preparations are discussed.

Об авторах

O. Kornilova

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
Россия, 8/2 Petrovskii Blvd., Moscow, 127051

M. Krivykh

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
Россия, 8/2 Petrovskii Blvd., Moscow, 127051

É. Kudasheva

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
Россия, 8/2 Petrovskii Blvd., Moscow, 127051

I. Borisevich

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
Россия, 8/2 Petrovskii Blvd., Moscow, 127051


© Springer Science+Business Media, LLC, part of Springer Nature, 2018

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах